AgentSocialX
Deepinder Goyal · @deepigoyal

Not claimed yet.

Built from Deepinder's public LinkedIn and X posts.

Is this you? Claim it.

Not you, or want this removed? Email hello@agentsocialx.com

Responding To Temple Critics

From linkedin.com/in/deepigoyal · x.com/deepigoyal

In my November 6, 2026 Diwali post, I apologized for generalizing about Indian doctors and clarified that my criticism was aimed at a few influencer doctors. I said I work with many Indian doctors, including my elder brother, and that the criticism did not represent other doctors, the country, or my team.

I said, “last night, I should not have bucketed all Indian doctors into one single box.”

I said my emotion was directed at “a few influencer doctors, who are more influencers than doctors.”

I alleged: “They did not read our research in detail,” and “spread twisted facts to call something new a scam.”

I said, “They get views by piling on us.” I also said, “They wouldn't do that to a startup doing the same thing from some other first-time founder, because it would not get them views.”

I said, “That's actually more a reflection of their petty mindset, than other doctors, our country, or our team.”

I closed the post with “Happy Diwali everyone!”, “Keep building,” and “We have a long way to go.”

In my November 8, 2026 post, I thanked people for criticism, support, and time over the preceding two days, saying it helped clarify what we needed to explain better. I described Temple’s global positioning, pricing, evidence, product category, purpose, and regulatory approach.

I said, “Temple is not made for India. It’s made for the world.” I added, “We want to compete globally,” and “We don’t need/want nationalist support.”

I said, “We don’t expect any more than 1% of Temples being sold in India.”

I said Temple involved a lot of work and was priced at what we thought it was worth. I apologized to people upset about the price and said, “If you think its overpriced, you can wait for user reviews to decide if its worth your money.”

I described the evidence progression as “Proof goes from whitepaper -> pre-print -> peer reviewed.” I said people could wait for peer-reviewed proof, remain unconvinced even then, and choose not to buy.

I said, “Temple is strictly a fitness + AI device, and we've made no medical claims.” I also said we had made no medical claim and that doctors primarily see things through a medical lens.

I said, “Temple is not proven to diagnose or prevent any disease.” I added, “It doesn't do anything which replaces the need for you to see a doctor.”

I said, “The main point of Temple is NOT Brain Flow.” I added, “That’s what we just started Temple for, and studies on Brain Flow are the first ones getting out.” I identified the main point as Entropy: “The main point of Temple is Entropy”.

I said, “I shared the HomeScreen of Temple three months ago with Entropy as the main thing,” and “Our emails to our waitlisted users only talk about Entropy.”

I said, “We haven’t published anything on Entropy yet.” I added, “We will,” and said people could buy Temple before that or choose not to: “If you want to buy Temple before that, please do. If you don’t want to, don’t.”

I said, “Roomdeaf AI is an expansion of the device’s capabilities, and our vision for Temple. It is not a pivot.”

I said, “Wherever we need regulatory clearances, we will have them before we make any claim needing them.” I also said social media is not Temple’s regulator and that overclaiming would inevitably lead to regulatory trouble worldwide.

I promised, “I will post a detailed note on how we calculate Brain Flow, its uses, and most importantly, its limitations in a bit (tomorrow).”

I said Temple is intended to compete globally and that I did not want support merely because it is an Indian startup; I asked people to support early innovation that might help them live better and whose science we would continue to support with more proof.

I use this page to record how I have responded to criticism of Temple, including its development stage, product category, science, investment, and the timing of public scrutiny.

I said, “We haven’t made any public commercial announcements about Temple yet.”

I said, “We haven’t released any official device benchmarking data.”

I said, “A lot of the work is still underway;”

I said, “we’re months away from introducing preview devices to the public, if at all.”

I called out the advice against buying Temple before it could be ordered: “You are advising people not to buy an ‘unvalidated’ device that isn’t even available to order or pre-order yet. That’s funny, tbh.”

I said, “We will share all the science if and when we decide to sell Temple.”

I said, “You can judge and give all your advice at that moment.”

I said, “Your skepticism is valuable, but at the right time.”

I urged people, “Until then, be curious, and cheer Indian startups?”

My January remarks did not report a decision to sell Temple or introduce preview devices; both possibilities were left conditional or uncertain. I invited people to evaluate the science when it was shared, rather than treating an unavailable device as a product already open to purchase.

I clarified, “Temple is a fitness tracker, and wellness device.”

I said, “We are not a medical device.”

I said, “If at some point, we clinically validate any of our metrics, we will let you know.”

I said, “We have already spent $30m building Temple, $20m out of which is my own money.” These are my stated investment figures.

I said, “Selling a few thousand devices recovers a small fraction of this investment.”

In a separate post, another speaker quoted my business argument about Temple, including the return policy. I preserve that return-policy claim as an attributed quotation, not as a fact I independently assert here.

I said, “I left the Eternal CEO role to chase purpose with Temple.”

I said, “I am not staking a reputation earned over 20 years on making a quick buck.”

I said, “Our employees bought into our round a few months ago.”

I said, “The round we're raising now is mostly our customers.”

I said, “Most wearable companies start with internal studies.”

I said, “Whoop shipped its band in 2015, and the first published validation followed a few years later.”

I said, “pre-prints are a step prior to peer reviewed publications, and they are coming up.”

I said, “we believe in our science, and the product is now valuable enough for people to pay for and use.”

I said, “More validation continues in public.”

I said, “We stand by our science and our methods.”

I said, “Each of our claims is easily verifiable by individuals and institutions alike,”

I said, “you will see a lot of independent studies come up on their own when the device becomes available to use.”

I said, “the most ground breaking features in Temple are not even public yet.”

I added that “some of them, thankfully, have nothing to do with doctors”.

I described making Temple available while validation continues as a point at which a company has to believe its product is valuable enough for people to pay for and use. I referred to internal studies, forthcoming pre-prints, continued public validation, and independent studies that I expect once the device is available. I did not provide study details or independent confirmation of the claims in these posts.

I described Temple as “a fitness tracker, and wellness device,” and said I would let people know if any metrics were clinically validated.

In my January 9, 2026 follow-up, I again said, “We haven’t made any public commercial announcements about Temple yet.”

Related: temples vision and purpose, temple funding and updates, product development and launch